We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 29, 2021

Effects of Canagliflozin on Serum Potassium in People With Diabetes and Chronic Kidney Disease

European Heart Journal


Additional Info

European Heart Journal
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Eur Heart J 2021 Dec 21;42(48)4891-4901, BL Neuen, M Oshima, V Perkovic, R Agarwal, C Arnott, G Bakris, CP Cannon, DM Charytan, R Edwards, JL Górriz, MJ Jardine, A Levin, B Neal, L De Nicola, C Pollock, N Rosenthal, DC Wheeler, KW Mahaffey, HJL Heerspink

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading